Goldman Sachs downgrades iHeartMedia to Sell, warning that shifting audio consumption and ad trends threaten growth, even as the company's TikTok partnership aims to capture younger audiences.
After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
Boston Scientific's latest earnings beat and raised guidance, fueled by strong demand for its electrophysiology devices, signal a strategic shift. The company is navigating tariff pressures while expanding margins, with major acquisitions poised to reshape its long-term profile.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
In Thailand's crucial northeast, a profound political realignment is underway. Farmers, disillusioned by unmet promises and economic hardship, are abandoning decades of party loyalty to back individual candidates, testing the foundations of the Shinawatra family's political machine ahead of pivotal elections.
Brookfield Renewable (BEPC) reported robust 2025 financial results, deploying a record $8.9 billion in capital. CEO Conor Teskey outlined a pivotal market transition, driven by surging electricity demand from data centers and industrial activity, positioning the company's diversified portfolio of hydro, wind, solar, and storage for accelerated growth.
Barclays' upgrade of PTC Therapeutics to Overweight has spotlighted the biotech firm's valuation, with shares showing strong momentum but questions lingering over its path to profitability and reliance on a narrow drug portfolio.
Medtronic secures a key European regulatory nod for its latest pulsed field ablation catheter while deepening its collaboration with Mindray, signaling a strategic push into high-growth areas of cardiac care and ambulatory surgery.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
SanDisk's Q2 2026 earnings reveal a 31% sequential revenue surge to $3 billion, driven by AI infrastructure build-out. The company highlights a fundamental industry shift towards long-term agreements as data center demand, now the largest NAND market, reshapes commercial dynamics.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
Amid a volatile economic backdrop, consumer discretionary stocks are lagging the broader market. We examine three companies—Columbia Sportswear, Movado, and iHeartMedia—whose business models and valuations make them vulnerable in the current climate.
With its stock near 52-week highs, Western Digital prepares to unveil its AI-driven storage roadmap at a pivotal New York event, seeking to transition its narrative from cyclical recovery to structural growth.
Once the engine of Venezuela's wealth, the communities around Lake Maracaibo now stand as decaying monuments to the nation's oil collapse. As a controversial U.S. plan promises a $100 billion investment, residents of the ghostly 'oil camps' are caught between desperate hope and deep-seated skepticism.
A 65-year-old Albany woman, remembered by family as 'the heart of the family,' was fatally shot in her home by a man she had housed for ten years, who then turned the gun on himself.
Following the release of 5-year-old Liam Conejo Ramos and his father from ICE detention, Texas Representative Joaquin Castro accompanied them home and penned a heartfelt letter, telling Liam he 'moved the world' and highlighting the ongoing debate over U.S. immigration enforcement.
As the Federal Reserve prepares for a potential policy shift in 2026, analysts flag real estate, financials, energy, and consumer discretionary as vulnerable sectors. Structural challenges and changing macroeconomic conditions could pressure performance despite broader market gains.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
